Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?

Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for... Current clinical guidelines emphasize the unmet need for technological innovations to guide physician decision-making and to transit from conventional care to personalized cardiovascular medicine. Biomarker-guided cardiovascular therapy represents an interesting approach to inform tailored treatment selection and monitor ongoing efficacy. However, results from previous publications cast some doubts about the clinical applicability of biomarkers to direct individualized treatment. In recent years, the non-coding human transcriptome has emerged as a new opportunity for the development of novel therapeutic strategies and biomarker discovery. Non-coding RNA (ncRNA) signatures may provide an accurate molecular fingerprint of patient phenotypes and capture levels of information that could complement traditional markers and established clinical variables. Importantly, ncRNAs have been identified in body fluids and their concentrations change with physiology and pathology, thus representing promising non-invasive biomarkers. Previous publications highlight the translational applicability of circulating ncRNAs for diagnosis and prognostic stratification within cardiology. Numerous independent studies have also evaluated the potential of the circulating non-coding transcriptome to predict and monitor response to cardiovascular treatment. However, this field has not been reviewed in detail. Here, we discuss the state-of-the-art research into circulating ncRNAs, specifically microRNAs and long non-coding RNAs, to support clinical decision-making in cardiovascular therapy. Furthermore, we summarize current methodological and conceptual limitations and propose future steps for their incorporation into personalized cardiology. Despite the lack of robust population-based studies and technical barriers, circulating ncRNAs emerge as a promising tool for biomarker-guided therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Heart Journal Oxford University Press

Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?

Download PDF
10 pages

Loading next page...
 
/lp/ou_press/circulating-non-coding-rnas-in-biomarker-guided-cardiovascular-therapy-jqKDf3iPHf
Publisher
Oxford University Press
Copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.
ISSN
0195-668X
eISSN
1522-9645
DOI
10.1093/eurheartj/ehy234
Publisher site
See Article on Publisher Site

Abstract

Current clinical guidelines emphasize the unmet need for technological innovations to guide physician decision-making and to transit from conventional care to personalized cardiovascular medicine. Biomarker-guided cardiovascular therapy represents an interesting approach to inform tailored treatment selection and monitor ongoing efficacy. However, results from previous publications cast some doubts about the clinical applicability of biomarkers to direct individualized treatment. In recent years, the non-coding human transcriptome has emerged as a new opportunity for the development of novel therapeutic strategies and biomarker discovery. Non-coding RNA (ncRNA) signatures may provide an accurate molecular fingerprint of patient phenotypes and capture levels of information that could complement traditional markers and established clinical variables. Importantly, ncRNAs have been identified in body fluids and their concentrations change with physiology and pathology, thus representing promising non-invasive biomarkers. Previous publications highlight the translational applicability of circulating ncRNAs for diagnosis and prognostic stratification within cardiology. Numerous independent studies have also evaluated the potential of the circulating non-coding transcriptome to predict and monitor response to cardiovascular treatment. However, this field has not been reviewed in detail. Here, we discuss the state-of-the-art research into circulating ncRNAs, specifically microRNAs and long non-coding RNAs, to support clinical decision-making in cardiovascular therapy. Furthermore, we summarize current methodological and conceptual limitations and propose future steps for their incorporation into personalized cardiology. Despite the lack of robust population-based studies and technical barriers, circulating ncRNAs emerge as a promising tool for biomarker-guided therapy.

Journal

European Heart Journal – Oxford University Press

Published: Apr 24, 2018

Keywords: Biomarker; Cardiovascular disease; Long non-coding RNAs; MicroRNAs; Non-coding RNAs; Personalized medicine; Precision medicine

References

  • 2016 ESC/EAS guidelines for the management of dyslipidaemias
    Catapano, AL; Graham, I; De Backer, G; Wiklund, O; Chapman, MJ; Drexel, H; Hoes, AW; Jennings, CS; Landmesser, U; Pedersen, TR; Reiner, Z; Riccardi, G; Taskinen, MR; Tokgozoglu, L; Verschuren, WM; Vlachopoulos, C; Wood, DA; Zamorano, JL.
  • 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
    Piepoli, MF; Hoes, AW; Agewall, S; Albus, C; Brotons, C; Catapano, AL; Cooney, MT; Corra, U; Cosyns, B; Deaton, C; Graham, I; Hall, MS; Hobbs, FDR; Lochen, ML; Lollgen, H; Marques-Vidal, P; Perk, J; Prescott, E; Redon, J; Richter, DJ; Sattar, N; Smulders, Y; Tiberi, M; van der Worp, HB; van Dis, I; Verschuren, WMM; Binno, S
  • Applied pharmacogenomics in cardiovascular medicine
    Weeke, P; Roden, DM.
  • Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the cholesterol and pharmacogenetics (cap) study
    Simon, JA; Lin, F; Hulley, SB; Blanche, PJ; Waters, D; Shiboski, S; Rotter, JI; Nickerson, DA; Yang, H; Saad, M; Krauss, RM.
  • Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects
    van der Leeuw, J; Ridker, PM; van der Graaf, Y; Visseren, FL.
  • Precision medicine in cardiology
    Antman, EM; Loscalzo, J.
  • Embracing complex associations in common traits: critical considerations for precision medicine
    Hall, MA; Moore, JH; Ritchie, MD.
  • Precision medicine—personalized, problematic, and promising
    Jameson, JL; Longo, DL.
  • Biomarker tests for molecularly targeted therapies—the key to unlocking precision medicine
    Lyman, GH; Moses, HL.
  • Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine
    Drucker, E; Krapfenbauer, K.
  • Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein
    Ridker, PM; Danielson, E; Fonseca, FA; Genest, J; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Shepherd, J; Willerson, JT; Glynn, RJ
  • Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association
    Chow, SL; Maisel, AS; Anand, I; Bozkurt, B; de Boer, RA; Felker, GM; Fonarow, GC; Greenberg, B; Januzzi, JL; Kiernan, MS; Liu, PP; Wang, TJ; Yancy, CW; Zile, MR.
  • Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction. A randomized clinical trial
    Felker, GM; Anstrom, KJ; Adams, KF; Ezekowitz, JA; Fiuzat, M; Houston-Miller, N; Januzzi, JL; Mark, DB; Piña, IL; Passmore, G; Whellan, DJ; Yang, H; Cooper, LS; Leifer, ES; Desvigne-Nickens, P; O’Connor, CM.
  • Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study)
    Epstein, RS; Moyer, TP; Aubert, RE; O’Kane, DJ; Xia, F; Verbrugge, RR; Gage, BF; Teagarden, JR.
  • The future of genetics and genomics: closing the phenotype gap in precision medicine
    MacRae, CA; Vasan, RS.
  • Genomics. Encode project writes eulogy for junk DNA
    Pennisi, E.
  • A meta-analysis of the genomic and transcriptomic composition of complex life
    Liu, G; Mattick, JS; Taft, RJ.
  • Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches
    Beermann, J; Piccoli, MT; Viereck, J; Thum, T.
  • Long noncoding RNAs: from clinical genetics to therapeutic targets?
    Boon, RA; Jae, N; Holdt, L; Dimmeler, S.
  • The mammalian transcriptome and the function of non-coding DNA sequences
    Shabalina, SA; Spiridonov, NA.
  • Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy
    Bar, C; Chatterjee, S; Thum, T.
  • Circular RNAs: clinical relevance in cancer
    Xu, Z; Yan, Y; Zeng, S; Dai, S; Chen, X; Wei, J; Gong, Z.
  • MicroRNA-21 contributes to myocardial disease by stimulating map kinase signalling in fibroblasts
    Thum, T; Gross, C; Fiedler, J; Fischer, T; Kissler, S; Bussen, M; Galuppo, P; Just, S; Rottbauer, W; Frantz, S; Castoldi, M; Soutschek, J; Koteliansky, V; Rosenwald, A; Basson, MA; Licht, JD; Pena, JT; Rouhanifard, SH; Muckenthaler, MU; Tuschl, T; Martin, GR; Bauersachs, J; Engelhardt, S.
  • The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
    Ucar, A; Gupta, SK; Fiedler, J; Erikci, E; Kardasinski, M; Batkai, S; Dangwal, S; Kumarswamy, R; Bang, C; Holzmann, A; Remke, J; Caprio, M; Jentzsch, C; Engelhardt, S; Geisendorf, S; Glas, C; Hofmann, TG; Nessling, M; Richter, K; Schiffer, M; Carrier, L; Napp, LC; Bauersachs, J; Chowdhury, K; Thum, T.
  • Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
    Poller, W; Dimmeler, S; Heymans, S; Zeller, T; Haas, J; Karakas, M; Leistner, DM; Jakob, P; Nakagawa, S; Blankenberg, S; Engelhardt, S; Thum, T; Weber, C; Meder, B; Hajjar, R; Landmesser, U.
  • Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischemic heart?
    Perrino, C; Barabasi, AL; Condorelli, G; Davidson, SM; De Windt, L; Dimmeler, S; Engel, FB; Hausenloy, DJ; Hill, JA; Van Laake, LW; Lecour, S; Leor, J; Madonna, R; Mayr, M; Prunier, F; Sluijter, JP; Schulz, R; Thum, T; Ytrehus, K; Ferdinandy, P.
  • MicroRNAs in heart failure: from biomarker to target for therapy
    Vegter, EL; van der Meer, P; de Windt, LJ; Pinto, YM; Voors, AA.
  • MicroRNAs within the continuum of postgenomics biomarker discovery
    Mayr, M; Zampetaki, A; Willeit, P; Willeit, J; Kiechl, S.
  • Long noncoding RNAs and microRNAs in cardiovascular pathophysiology
    Thum, T; Condorelli, G.
  • Circulating inflammatory miRNA signature in response to different doses of aerobic exercise
    de Gonzalo-Calvo, D; Dávalos, A; Montero, A; García-González, Á; Tyshkovska, I; González-Medina, A; Soares, SMA; Martínez-Camblor, P; Casas-Agustench, P; Rabadán, M; Díaz-Martínez, ÁE; Úbeda, N; Iglesias-Gutiérrez, E.
  • The microRNA spectrum in 12 body fluids
    Weber, JA; Baxter, DH; Zhang, S; Huang, DY; Huang, KH; Lee, MJ; Galas, DJ; Wang, K.
  • Circulating long noncoding RNA, lipcar, predicts survival in patients with heart failure
    Kumarswamy, R; Bauters, C; Volkmann, I; Maury, F; Fetisch, J; Holzmann, A; Lemesle, G; de Groote, P; Pinet, F; Thum, T.
  • Circulating microRNAs as stable blood-based markers for cancer detection
    Mitchell, PS; Parkin, RK; Kroh, EM; Fritz, BR; Wyman, SK; Pogosova-Agadjanyan, EL; Peterson, A; Noteboom, J; O’Briant, KC; Allen, A; Lin, DW; Urban, N; Drescher, CW; Knudsen, BS; Stirewalt, DL; Gentleman, R; Vessella, RL; Nelson, PS; Martin, DB; Tewari, M.
  • Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes
    de Gonzalo-Calvo, D; van der Meer, RW; Rijzewijk, LJ; Smit, JW; Revuelta-Lopez, E; Nasarre, L; Escola-Gil, JC; Lamb, HJ; Llorente-Cortes, V.
  • Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure
    Masson, S; Batkai, S; Beermann, J; Bar, C; Pfanne, A; Thum, S; Magnoli, M; Balconi, G; Nicolosi, GL; Tavazzi, L; Latini, R; Thum, T.
  • Long noncoding RNAs in patients with acute myocardial infarction
    Vausort, M; Wagner, DR; Devaux, Y.
  • MicroRNAs in cardiovascular disease: an introduction for clinicians
    Romaine, SP; Tomaszewski, M; Condorelli, G; Samani, NJ.
  • Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury
    Viereck, J; Thum, T.
  • Mirbase: annotating high confidence microRNAs using deep sequencing data
    Kozomara, A; Griffiths-Jones, S.
  • Most mammalian mRNAs are conserved targets of microRNAs
    Friedman, RC; Farh, KK; Burge, CB; Bartel, DP.
  • MicroRNAs in stress signaling and human disease
    Mendell, JT; Olson, EN.
  • Pervasive roles of microRNAs in cardiovascular biology
    Small, EM; Olson, EN.
  • Regulation of cardiac microRNAs by cardiac microRNAs
    Matkovich, SJ; Hu, Y; Dorn, GW
  • Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma
    Arroyo, JD; Chevillet, JR; Kroh, EM; Ruf, IK; Pritchard, CC; Gibson, DF; Mitchell, PS; Bennett, CF; Pogosova-Agadjanyan, EL; Stirewalt, DL; Tait, JF; Tewari, M.
  • Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease
    de Gonzalo-Calvo, D; Cenarro, A; Garlaschelli, K; Pellegatta, F; Vilades, D; Nasarre, L; Camino-Lopez, S; Crespo, J; Carreras, F; Leta, R; Catapano, AL; Norata, GD; Civeira, F; Llorente-Cortes, V.
  • Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs
    Hergenreider, E; Heydt, S; Treguer, K; Boettger, T; Horrevoets, AJ; Zeiher, AM; Scheffer, MP; Frangakis, AS; Yin, X; Mayr, M; Braun, T; Urbich, C; Boon, RA; Dimmeler, S.
  • An endocrine genetic signal between blood cells and vascular smooth muscle cells: role of microRNA-223 in smooth muscle function and atherogenesis
    Shan, Z; Qin, S; Li, W; Wu, W; Yang, J; Chu, M; Li, X; Huo, Y; Schaer, GL; Wang, S; Zhang, C.
  • Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy
    Bang, C; Batkai, S; Dangwal, S; Gupta, SK; Foinquinos, A; Holzmann, A; Just, A; Remke, J; Zimmer, K; Zeug, A; Ponimaskin, E; Schmiedl, A; Yin, X; Mayr, M; Halder, R; Fischer, A; Engelhardt, S; Wei, Y; Schober, A; Fiedler, J; Thum, T.
  • Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease
    de Boer, HC; van Solingen, C; Prins, J; Duijs, JM; Huisman, MV; Rabelink, TJ; van Zonneveld, AJ.
  • Circulating microRNAs as novel biomarkers for platelet activation
    Willeit, P; Zampetaki, A; Dudek, K; Kaudewitz, D; King, A; Kirkby, NS; Crosby-Nwaobi, R; Prokopi, M; Drozdov, I; Langley, SR; Sivaprasad, S; Markus, HS; Mitchell, JA; Warner, TD; Kiechl, S; Mayr, M.
  • Association of microRNAs and YRNAs with platelet function
    Kaudewitz, D; Skroblin, P; Bender, LH; Barwari, T; Willeit, P; Pechlaner, R; Sunderland, NP; Willeit, K; Morton, AC; Armstrong, PC; Chan, MV; Lu, R; Yin, X; Gracio, F; Dudek, K; Langley, SR; Zampetaki, A; de Rinaldis, E; Ye, S; Warner, TD; Saxena, A; Kiechl, S; Storey, RF; Mayr, M.
  • Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width
    Binderup, HG; Houlind, K; Madsen, JS; Brasen, CL.
  • Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity
    Kok, MG; Mandolini, C; Moerland, PD; de Ronde, MW; Sondermeijer, BM; Halliani, A; Nieuwland, R; Cipollone, F; Creemers, EE; Meijers, JC; Pinto-Sietsma, SJ.
  • Micro-array profiling exhibits remarkable intra-individual stability of human platelet micro-RNA
    Stratz, C; Nuhrenberg, TG; Binder, H; Valina, CM; Trenk, D; Hochholzer, W; Neumann, FJ; Fiebich, BL.
  • Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity
    Shi, R; Ge, L; Zhou, X; Ji, WJ; Lu, RY; Zhang, YY; Zeng, S; Liu, X; Zhao, JH; Zhang, WC; Jiang, TM; Li, YM.
  • Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders
    Marfella, R; Di Filippo, C; Potenza, N; Sardu, C; Rizzo, MR; Siniscalchi, M; Musacchio, E; Barbieri, M; Mauro, C; Mosca, N; Solimene, F; Mottola, MT; Russo, A; Rossi, F; Paolisso, G; D’Amico, M.
  • Circulating microRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study
    Melman, YF; Shah, R; Danielson, K; Xiao, J; Simonson, B; Barth, A; Chakir, K; Lewis, GD; Lavender, Z; Truong, QA; Kleber, A; Das, R; Rosenzweig, A; Wang, Y; Kass, DA; Singh, JP; Das, S.
  • Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device
    Morley-Smith, AC; Mills, A; Jacobs, S; Meyns, B; Rega, F; Simon, AR; Pepper, JR; Lyon, AR; Thum, T.
  • Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers
    Akat, KM; Moore-McGriff, D; Morozov, P; Brown, M; Gogakos, T; Correa Da Rosa, J; Mihailovic, A; Sauer, M; Ji, R; Ramarathnam, A; Totary-Jain, H; Williams, Z; Tuschl, T; Schulze, PC.
  • MicroRNA expression in myocardial tissue and plasma of patients with end-stage heart failure during lvad support: comparison of continuous and pulsatile devices
    Lok, SI; de Jonge, N; van Kuik, J; van Geffen, AJ; Huibers, MM; van der Weide, P; Siera, E; Winkens, B; Doevendans, PA; de Weger, RA; da Costa Martins, PA.
  • Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure
    Dickinson, BA; Semus, HM; Montgomery, RL; Stack, C; Latimer, PA; Lewton, SM; Lynch, JM; Hullinger, TG; Seto, AG; van Rooij, E.
  • . Precision medicine in patients with resistant hypertension and obstructive sleep apnea: blood pressure response to continuous positive airway pressure treatment
    Sánchez-de-la-Torre, M; Khalyfa, A; Sánchez-de-la-Torre, A; Martinez-Alonso, M; Martinez-García, MÁ; Barceló, A; Lloberes, P; Campos-Rodriguez, F; Capote, F; Diaz-de-Atauri, MJ; Somoza, M; González, M; Masa, J-F; Gozal, D; Barbé, F
  • Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
    Kuliczkowski, W; Witkowski, A; Polonski, L; Watala, C; Filipiak, K; Budaj, A; Golanski, J; Sitkiewicz, D; Pregowski, J; Gorski, J; Zembala, M; Opolski, G; Huber, K; Arnesen, H; Kristensen, SD; De Caterina, R.
  • Comparison of aggregometry with flow cytometry for the assessment of agonists-induced platelet reactivity in patients on dual antiplatelet therapy
    Gremmel, T; Koppensteiner, R; Panzer, S.
  • 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)
    Brignole, M; Auricchio, A; Baron-Esquivias, G; Bordachar, P; Boriani, G; Breithardt, OA; Cleland, J; Deharo, JC; Delgado, V; Elliott, PM; Gorenek, B; Israel, CW; Leclercq, C; Linde, C; Mont, L; Padeletti, L; Sutton, R; Vardas, PE; Zamorano, JL; Achenbach, S; Baumgartner, H; Bax, JJ; Bueno, H; Dean, V; Deaton, C; Erol, C; Fagard, R; Ferrari, R; Hasdai, D; Hoes, AW; Kirchhof, P; Knuuti, J; Kolh, P; Lancellotti, P; Linhart, A; Nihoyannopoulos, P; Piepoli, MF; Ponikowski, P; Sirnes, PA; Tamargo, JL; Tendera, M; Torbicki, A; Wijns, W; Windecker, S; Document, R; Kirchhof, P; Blomstrom-Lundqvist, C; Badano, LP; Aliyev, F; Bansch, D; Baumgartner, H; Bsata, W; Buser, P; Charron, P; Daubert, JC; Dobreanu, D; Faerestrand, S; Hasdai, D; Hoes, AW; Le Heuzey, JY; Mavrakis, H; McDonagh, T; Merino, JL; Nawar, MM; Nielsen, JC; Pieske, B; Poposka, L; Ruschitzka, F; Tendera, M; Van Gelder, IC; Wilson, CM.
  • Avoiding non-responders to cardiac resynchronization therapy: a practical guide
    Daubert, C; Behar, N; Martins, RP; Mabo, P; Leclercq, C.
  • Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure
    Baras Shreibati, J; Goldhaber-Fiebert, JD; Banerjee, D; Owens, DK; Hlatky, MA.
  • Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes
    Gustafsson, F; Rogers, JG.
  • The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: executive summary
    Feldman, D; Pamboukian, SV; Teuteberg, JJ; Birks, E; Lietz, K; Moore, SA; Morgan, JA; Arabia, F; Bauman, ME; Buchholz, HW; Deng, M; Dickstein, ML; El-Banayosy, A; Elliot, T; Goldstein, DJ; Grady, KL; Jones, K; Hryniewicz, K; John, R; Kaan, A; Kusne, S; Loebe, M; Massicotte, MP; Moazami, N; Mohacsi, P; Mooney, M; Nelson, T; Pagani, F; Perry, W; Potapov, EV; Eduardo Rame, J; Russell, SD; Sorensen, EN; Sun, B; Strueber, M; Mangi, AA; Petty, MG; Rogers, J.
  • Long noncoding RNAs in cardiovascular diseases
    Uchida, S; Dimmeler, S.
  • Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs
    Ounzain, S; Micheletti, R; Beckmann, T; Schroen, B; Alexanian, M; Pezzuto, I; Crippa, S; Nemir, M; Sarre, A; Johnson, R; Dauvillier, J; Burdet, F; Ibberson, M; Guigo, R; Xenarios, I; Heymans, S; Pedrazzini, T.
  • Creating reference gene annotation for the mouse c57bl6/j genome assembly
    Mudge, JM; Harrow, J.
  • Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes
    de Gonzalo-Calvo, D; Kenneweg, F; Bang, C; Toro, R; van der Meer, RW; Rijzewijk, LJ; Smit, JW; Lamb, HJ; Llorente-Cortes, V; Thum, T.
  • Exosome-transmitted lncarsr promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA
    Qu, L; Ding, J; Chen, C; Wu, ZJ; Liu, B; Gao, Y; Chen, W; Liu, F; Sun, W; Li, XF; Wang, X; Wang, Y; Xu, ZY; Gao, L; Yang, Q; Xu, B; Li, YM; Fang, ZY; Xu, ZP; Bao, Y; Wu, DS; Miao, X; Sun, HY; Sun, YH; Wang, HY; Wang, LH.
  • Circulating long noncoding RNAs in personalized medicine: response to pioglitazone therapy in type 2 diabetes
    de Gonzalo-Calvo, D; Kenneweg, F; Bang, C; Toro, R; van der Meer, RW; Rijzewijk, LJ; Smit, JW; Lamb, HJ; Llorente-Cortes, V; Thum, T.
  • Circular RNAs in heart failure
    Devaux, Y; Creemers, EE; Boon, RA; Werfel, S; Thum, T; Engelhardt, S; Dimmeler, S; Squire, I.
  • Epidemiological studies of CHD and the evolution of preventive cardiology
    Wong, ND.
  • Evolocumab and clinical outcomes in patients with cardiovascular disease
    Sabatine, MS; Giugliano, RP; Keech, AC; Honarpour, N; Wiviott, SD; Murphy, SA; Kuder, JF; Wang, H; Liu, T; Wasserman, SM; Sever, PS; Pedersen, TR
  • Antiinflammatory therapy with canakinumab for atherosclerotic disease
    Ridker, PM; Everett, BM; Thuren, T; MacFadyen, JG; Chang, WH; Ballantyne, C; Fonseca, F; Nicolau, J; Koenig, W; Anker, SD; Kastelein, JJP; Cornel, JH; Pais, P; Pella, D; Genest, J; Cifkova, R; Lorenzatti, A; Forster, T; Kobalava, Z; Vida-Simiti, L; Flather, M; Shimokawa, H; Ogawa, H; Dellborg, M; Rossi, PRF; Troquay, RPT; Libby, P; Glynn, RJ; Group, CT.
  • Pcsk9 inhibitors: economics and policy
    Hlatky, MA; Kazi, DS.